What Is MK-677?
MK-677 (Ibutamoren, Nutrobal, L-163,191) is a non-peptide, orally active ghrelin receptor (GHSR-1a) agonist discovered at Merck Research Laboratories. It was developed as a drug candidate for muscle wasting, frailty, osteoporosis, and GH deficiency — conditions where increasing GH and IGF-1 levels is therapeutically hypothesized to be beneficial.
Unlike peptide GH secretagogues (CJC-1295, Ipamorelin, GHRP-6), MK-677 is a small molecule with oral bioavailability and a long half-life (~24 hours in humans). This makes it pharmacologically distinct and practically different in research protocols.
Despite being grouped with SARMs in the research chemical market, MK-677 does not bind the androgen receptor — it is an orexigenic ghrelin receptor agonist. It is prohibited in sport under WADA S2 (peptide hormones, growth factors, and related substances).
Ghrelin Receptor Mechanism
Ghrelin is an endogenous peptide hormone produced primarily by the stomach. It acts on the growth hormone secretagogue receptor type 1a (GHSR-1a) in the hypothalamus and pituitary, stimulating GH release. MK-677 mimics ghrelin's GHSR-1a agonism as a small molecule:
- Pituitary: Direct stimulation of somatotroph cells → GH release in pulses
- Hypothalamus: GHSR-1a stimulation → increased GHRH secretion and reduced somatostatin tone (somatostatin inhibits GH release; its suppression amplifies GH pulses)
- Synergy with GHRH: MK-677 and GHRH analogues (CJC-1295) act on different receptors — their combined effect is synergistic and greater than either alone
The net result is increased pulsatile GH secretion and sustained elevation of IGF-1 (produced in liver in response to GH).
GH/IGF-1 Axis Effects
MK-677's downstream effects are primarily mediated through the GH/IGF-1 axis:
- IGF-1 elevation: Sustained, dose-dependent elevation of serum IGF-1. At 25 mg/day in humans, MK-677 increases IGF-1 by approximately 60–90% (Nass et al., 2008).
- GH pulse amplification: Increases GH pulse amplitude while largely preserving pulsatile pattern (vs continuous GH infusion which suppresses pulses)
- Bone turnover markers: MK-677 increases osteocalcin and alkaline phosphatase — bone formation markers — in multiple human studies
- Fat metabolism: IGF-1 increases and GH-mediated lipolysis, though some studies show transient insulin resistance with MK-677 at higher doses
Phase II Clinical Data
MK-677 has one of the most extensive human clinical trial datasets of any research SARM-adjacent compound:
| Study | Population | Duration | Key Finding |
|---|---|---|---|
| Chapman et al. (1996) | Healthy elderly (65+) | 2 weeks | Dose-dependent GH and IGF-1 increases; 25mg dose well tolerated |
| Svensson et al. (1998) | Obese men | 8 weeks | Fat-selective metabolic effects; no significant change in lean mass short-term |
| Nass et al. (2008) | Elderly (60–81) | 24 months | Significant lean mass +1.6kg vs placebo; improved muscle strength; sustained IGF-1 elevation |
| Murphy et al. (1998) | GH-deficient adults | 12 months | IGF-1 normalization; lean mass and bone density effects comparable to GH injection |
The Nass et al. 2-year study is particularly significant: it remains one of the few SARM/secretagogue compounds with a 2-year randomized controlled trial demonstrating statistically significant lean mass effects in humans.
Muscle & Aging Research
The primary research applications for MK-677 in academic settings:
- Sarcopenia: Age-related muscle loss driven partly by declining GH/IGF-1 secretion — MK-677 reverses the GH/IGF-1 decline without testosterone or GHRH injection requirements
- Hip fracture recovery: A Phase III trial in hip fracture patients examined whether MK-677-driven IGF-1 restoration could improve functional recovery
- Sleep GH pulsatility: GH is secreted predominantly during slow-wave sleep; MK-677 amplifies nocturnal GH pulses — relevant for aging biology and sleep-GH relationship research
- Bone density: Multiple studies show MK-677 increases bone turnover markers and bone mineral density over 12–24 months in elderly subjects
MK-677 vs Peptide Secretagogues
| Parameter | MK-677 | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Mechanism | Ghrelin receptor (GHSR-1a) | GHRH receptor | Ghrelin receptor (GHSR-1a) |
| Route | Oral | Injectable | Injectable |
| Half-life | ~24h (humans) | ~8 days (with DAC) | ~2h |
| GH pulse effect | Sustained elevation | Sustained GHRH signalling | Selective pulse |
| IGF-1 elevation | Yes (60-90%) | Yes | Modest |
| Human RCT data | Yes (2-year Nass 2008) | Limited | Limited |
| Cortisol/prolactin | Mild elevation | None | None |
For chronic research models requiring sustained GH/IGF-1 elevation without injection, MK-677 is the practical choice. For acute GH pulse timing studies or cleaner selectivity, Ipamorelin or CJC-1295 are more appropriate tools.